Selection of Detection Methods for Hepatobiliary Metabolism-Related Indicators
Selection of Detection Methods for Hepatobiliary Metabolism-Related Indicators
Detection of hepatobiliary metabolism-related indicators is used to evaluate hepatocyte synthesis and transport, bile formation, biliary excretion, cholestasis, cholesterol homeostasis, and bile discharge function from the perspectives of bile acids, bilirubin, cholesterol, cholesterol esters, lipoprotein transport, hepatic lipid processing, and gallbladder functional regulation.
Keywords: hepatobiliary metabolism; bile acid detection; bilirubin detection; cholesterol detection; cholesterol ester; hepatic lipase; urinary bilirubin; urobilinogen
1 Indicator Framework for Hepatobiliary Metabolism Detection
1.1 Bile Acid-Related Indicators
(1) Total bile acids
Total bile acids (TBA) reflect the overall bile acid level in a sample and are suitable for preliminary evaluation of cholestasis, abnormal hepatobiliary excretion, and changes in bile acid synthesis or transport. Serum, plasma, bile, liver tissue, intestinal contents, and cell models can all be selected for TBA detection according to the experimental objective. However, absolute values from different sample types should not be directly compared; interpretation should take dilution factor, normalization method, and sampling site into account.
(2) Bile acid components
Cholic acid, chenodeoxycholic acid, deoxycholic acid, ursodeoxycholic acid, lithocholic acid, and their glycine- or taurine-conjugated derivatives together constitute the bile acid profile. An increase in total bile acids only indicates an overall change in bile acid levels and cannot determine whether the proportions of primary bile acids, secondary bile acids, or conjugated bile acids have changed. For studies involving bile acid synthesis, enterohepatic circulation, and gut microbiota-mediated metabolism, component analysis using HPLC, UPLC, or LC-MS/MS should be performed.
1.2 Bilirubin and Bile Pigment Excretion Indicators
(1) Total bilirubin and direct bilirubin
Total bilirubin (TBIL) reflects the overall bilirubin level, while direct bilirubin (DBIL) is more closely associated with conjugated bilirubin and bile excretion-related changes. Hepatocellular injury, cholestasis, biliary obstruction, and abnormal bile pigment excretion may all lead to changes in bilirubin indicators. Therefore, TBIL and DBIL are more suitable as supporting indicators for evaluating hepatobiliary excretory status and should not be used alone to explain all changes in hepatobiliary metabolism.
(2) Urinary bilirubin and urobilinogen
Urinary bilirubin and urobilinogen are auxiliary urinary indicators related to bile pigment metabolism. Positive urinary bilirubin often suggests that conjugated bilirubin has entered the urine, whereas changes in urobilinogen are associated with bilirubin enterohepatic circulation, hepatocellular processing capacity, and biliary excretion status. These two indicators are suitable for auxiliary screening of hepatobiliary excretory abnormalities, but should be interpreted together with serum bilirubin, bile acids, and the background of the experimental model.
1.3 Cholesterol and Biliary Lipid Indicators
(1) Total cholesterol and free cholesterol
Cholesterol is an important component of biliary lipids. The ratio of cholesterol, bile acids, and phospholipids in bile affects cholesterol solubility and crystallization risk. Total cholesterol (TC) is suitable for evaluating overall cholesterol levels, whereas free cholesterol (FC) is more appropriate for analyzing cholesterol crystallization, gallstone formation, and biliary lipid stability.
(2) Cholesterol esters
Cholesterol esters (CE) are commonly used to evaluate cholesterol storage, transport, and esterification status. Cholesterol ester detection in liquid samples is suitable for serum, plasma, or bile-related systems, whereas cholesterol ester detection in tissues and cells is more suitable for liver tissue, gallbladder tissue, macrophages, hepatocytes, or cholesterol metabolism models. CE results usually need to be interpreted together with TC, FC, and lipoprotein indicators.
1.4 Hepatobiliary Regulatory and Functional Indicators
(1) Cholesterol transport and bile acid synthesis
CYP7A1 participates in the rate-limiting step of cholesterol conversion into bile acids, NPC1L1 is associated with cholesterol absorption, and LCAT is involved in cholesterol esterification and lipoprotein metabolism. These indicators are not equivalent to direct measurements of bile acid or cholesterol content, but they can be used to explain regulatory mechanisms related to cholesterol homeostasis, bile acid synthesis, and enterohepatic circulation.
(2) Hepatic lipid transport and lipase activity
Hepatic lipase (HL) participates in the hydrolysis of lipoproteins and triglycerides, while liver-type fatty acid-binding protein (FABP1/LFABP) is associated with hepatocellular fatty acid transport, lipid metabolism, and hepatocellular injury. These indicators are suitable as mechanistic supplements for assessing hepatic lipid processing capacity and hepatocellular metabolic status, but should not replace content measurements such as TC, FC, CE, or TBA.
(3) Gallbladder contraction and bile secretion regulation
Cholecystokinin (CCK) and its receptor are associated with gallbladder contraction, bile discharge, and digestion. In studies of gallbladder function, bile excretion dynamics, or cholestasis, CCK or CCKAR can be used as functional regulatory indicators. However, their results should be analyzed together with bile acids, bilirubin, and bile flow.
Table 1 Hepatobiliary Metabolism-Related Indicators and Detection Positioning
Indicator Category | Representative Indicators | Recommended Methods | Main Samples | Application Positioning |
Total bile acids | TBA | Enzymatic assay, microassay, colorimetric assay | Serum, plasma, bile, tissue, cells | Evaluation of cholestasis, bile acid metabolism, and hepatobiliary excretion |
Bile acid components | CA, CDCA, DCA, LCA, UDCA, and conjugated bile acids | HPLC, UPLC, LC-MS/MS | Bile, serum, feces, tissue | Bile acid profiling, enterohepatic circulation, and gut microbiota metabolism studies |
Bilirubin metabolism | TBIL, DBIL, urinary bilirubin, urobilinogen | Colorimetric assay, qualitative chromogenic assay, microassay | Serum, urine, bile, tissue | Evaluation of bile pigment metabolism, cholestasis, and biliary excretion |
Cholesterol metabolism | TC, FC, CE | COD-PAP method, colorimetric assay, fluorescence assay | Serum, bile, tissue, cells | Biliary lipid composition, gallstone risk, and cholesterol homeostasis |
Lipoprotein cholesterol | LDL-C, HDL-C | COD-PAP method, colorimetric assay | Serum, plasma | Auxiliary evaluation of hepatic lipid transport and blood lipid metabolism |
Hepatic lipid processing | HL, FABP1/LFABP | Activity assay, ELISA | Serum, tissue, cells | Auxiliary evaluation of hepatic lipid hydrolysis, fatty acid transport, and hepatocellular injury |
Regulatory factors | CYP7A1, NPC1L1, LCAT, CCK, CCKAR | ELISA, immunoassay, molecular detection | Serum, tissue, cells | Mechanistic studies of bile acid synthesis, cholesterol transport, and gallbladder function |
2 Selection of Detection Methods
2.1 Enzymatic and Colorimetric Assays
(1) Method positioning
Enzymatic and colorimetric assays are suitable for routine content detection of total bile acids, bilirubin, cholesterol, free cholesterol, cholesterol esters, and related indicators. These methods are relatively standardized and suitable for multi-sample comparison and model screening. However, they are sensitive to sample color, turbidity, lipid background, and dilution factor. Sample blanks are particularly important for bile, tissue homogenates, and hyperlipidemic samples.
(2) Scope of application
Enzymatic and colorimetric assays can be used for total-level evaluation, but they do not provide molecular component information. Increased total bile acids, cholesterol, or bilirubin only indicates that a certain indicator category has changed; it cannot directly identify specific bile acid components, bilirubin conjugation status, or lipid profile structure. Therefore, mechanistic studies often require combined analysis with LC-MS/MS, HPLC, or immunoassays.
2.2 Microassays and High-Throughput Detection
(1) Method positioning
Microassays are suitable for experiments with limited sample volume or multi-well plate-based batch detection, such as mouse serum, micro-volume bile samples, tissue homogenates, cell lysates, and culture supernatants. This approach reduces sample consumption and improves detection throughput, but it requires higher precision in pipetting, inter-well consistency, and standard curve quality.
(2) Quality control
In microassays, the standard curve, sample dilution, replicate consistency, and blank subtraction are critical for reliable results. Bile samples, lipid-rich samples, and deeply colored samples should first undergo pilot testing to confirm that diluted readings fall within the linear range before formal batch detection.
2.3 Qualitative Chromogenic Assays
(1) Method positioning
Urinary bilirubin and urobilinogen are commonly detected using qualitative or semi-quantitative chromogenic assays, which serve as auxiliary indicators for bile pigment metabolism and hepatobiliary excretory abnormalities. Qualitative urinary bilirubin detection reflects the excretion of conjugated bilirubin into urine, while urobilinogen detection is associated with bilirubin enterohepatic circulation and hepatocellular processing capacity.
(2) Scope of application
Qualitative urine testing is suitable for screening and trend evaluation, but should not replace serum bilirubin, total bile acid, or bile acid profiling analysis. Urine concentration, sampling time, storage conditions, and drug interference may all affect results; therefore, findings should be interpreted together with blood indicators, tissue indicators, or the experimental model background.
2.4 Activity Assays and ELISA
(1) Enzyme activity assays
Hepatic lipase or hepatic esterase activity assays are suitable for evaluating hepatic lipid hydrolysis and lipoprotein metabolism. These methods detect changes in enzyme function and are not equivalent to content measurements of cholesterol, cholesterol esters, or lipoprotein cholesterol. When used in lipid metabolism studies, they should be analyzed together with TC, FC, CE, LDL-C, and HDL-C.
(2) ELISA detection
ELISA is suitable for detecting protein or peptide regulatory factors such as LCAT, CYP7A1, NPC1L1, CCK, CCKAR, BLVRB, and FABP1/LFABP, and is used to explain changes in hepatobiliary metabolic pathways. These indicators are more mechanistically oriented and cannot directly replace content detection of TBA, TBIL, DBIL, or TC.
2.5 HPLC, UPLC, and LC-MS/MS
(1) Method positioning
HPLC, UPLC, and LC-MS/MS are suitable for bile acid profiling, lipid profiling, and complex metabolite component analysis. LC-MS/MS can simultaneously detect multiple free, glycine-conjugated, and taurine-conjugated bile acids, and can further resolve bile acid synthesis, conversion, and enterohepatic circulation patterns.
(2) Scope of application
Chromatographic and mass spectrometric methods provide high information content, but they require higher standards for reference materials, internal standards, sample pretreatment, instrumental conditions, and data analysis. If the experimental objective is only large-sample total-level screening, enzymatic or colorimetric assays are more efficient. If the objective is to interpret metabolic pathways and component remodeling, LC-MS/MS should be prioritized.
Table 2 Comparison of Common Detection Methods for Hepatobiliary Metabolism Indicators
Method Type | Applicable Indicators | Main Advantages | Main Limitations | Suitable Scenarios |
Enzymatic/colorimetric assay | TBA, TBIL, DBIL, TC, FC, CE | Standardized operation; suitable for routine content detection | Affected by color, turbidity, and matrix effects | Multi-sample screening, model comparison, routine detection |
Microassay | TBA, TBIL, DBIL, TC, FC, CE, HL | Low sample consumption; suitable for high-throughput detection | Requires high pipetting accuracy and validated linear range | Small-volume samples, animal experiments, cell models |
Qualitative chromogenic assay | Urinary bilirubin, urobilinogen | Simple operation; suitable for auxiliary screening | Limited quantitative capability | Urinary bile pigment metabolism evaluation |
Activity assay | HL and other metabolic enzymes | Directly reflects enzyme functional status | Does not represent total substrate or product levels | Hepatic lipid metabolism and enzyme function studies |
ELISA | LCAT, CYP7A1, NPC1L1, CCK, FABP1, etc. | Suitable for protein and regulatory factor detection | Does not represent metabolite content | Mechanistic studies and pathway regulation analysis |
HPLC/UPLC | Bile acids, cholesterol, selected lipid components | Enables component separation | Identification and sensitivity depend on detector performance | Component analysis and method development |
LC-MS/MS | Bile acid profile, lipidome, metabolome | Strong component-resolving capability | Requires instrumentation and internal standards | Bile acid metabolomics and enterohepatic circulation studies |
3 Detection Design for Different Sample Types
3.1 Serum and Plasma Samples
(1) Detection indicators
Serum and plasma are suitable for detecting TBA, TBIL, DBIL, TC, FC, CE, LDL-C, HDL-C, HL, and selected ELISA indicators. These measurements can be used to evaluate hepatobiliary excretion, bile pigment metabolism, blood lipid transport, lipoprotein hydrolysis, and cholesterol homeostasis. Blood collection status, postprandial timing, hemolysis, lipemia, anticoagulant system, and freeze-thaw cycles all affect result consistency.
(2) Method selection
Routine content indicators can be detected using microassays, colorimetric assays, or the COD-PAP method. Enzyme activity indicators can be measured using activity assay kits, protein regulatory indicators can be detected using ELISA, and bile acid profiling or lipid profiling should be performed by LC-MS/MS. In batch experiments, sample collection time, processing time, and storage conditions should be standardized to reduce non-experimental variation.
3.2 Urine Samples
(1) Detection indicators
Urine samples are more suitable for auxiliary detection of bile pigment metabolism, such as urinary bilirubin and urobilinogen. Positive urinary bilirubin is often associated with abnormal excretion of conjugated bilirubin, whereas changes in urobilinogen can reflect alterations in bilirubin enterohepatic circulation and hepatocellular processing capacity.
(2) Result interpretation
Urine test results are strongly affected by urine concentration, sampling time, storage conditions, and drug interference. Abnormal urinary bilirubin or urobilinogen should not be interpreted alone as evidence of a specific hepatobiliary disease or mechanistic change, but should be evaluated together with serum TBIL, DBIL, TBA, and the model background.
3.3 Bile Samples
(1) Detection indicators
Bile samples can be used to detect total bile acids, bilirubin, cholesterol, free cholesterol, cholesterol esters, and bile acid profiles. Target analyte concentrations in bile are usually high, and bile often has deep color, high viscosity, and abundant lipid and mucus components. Therefore, dilution, clarification, and sample blank correction require particular attention before detection.
(2) Method selection
Total-level screening can be performed using TBA, TBIL, TC, FC, and CE assay kits. Analysis of bile acid components, cholesterol metabolites, or lipid profiles should be conducted using HPLC, UPLC, or LC-MS/MS. Before formal bile sample detection, dilution linearity should be verified to avoid readings outside the standard curve range.
3.4 Tissue and Cell Samples
(1) Tissue samples
Liver tissue, gallbladder tissue, intestinal tissue, and biliary tract-related tissues can be used to detect bile acids, cholesterol, cholesterol esters, hepatic lipase activity, and regulatory proteins. Tissue sampling site, wet weight, homogenization ratio, and centrifugation conditions should be standardized. Results can be normalized to tissue weight, protein amount, or cell number.
(2) Cell samples
Hepatocytes, intestinal epithelial cells, cholangiocytes, macrophages, or cholesterol metabolism models can be used to assess intracellular cholesterol, cholesterol esters, bile acid processing capacity, and related protein expression. Cell experiments should include treatment blanks, lysis buffer blanks, and protein normalization to avoid bias caused by differences in cell number.
Table 3 Indicator Combinations for Different Sample Types
Sample Type | Recommended Indicators | Recommended Methods | Result Expression |
Serum/plasma | TBA, TBIL, DBIL, TC, FC, CE, LDL-C, HDL-C, HL | Microassay, colorimetric assay, COD-PAP method, activity assay, ELISA | Concentration, enzyme activity, or relative intergroup change |
Urine | Urinary bilirubin, urobilinogen | Harrison method, modified Ehrlich method | Qualitative or semi-quantitative results |
Bile | TBA, TBIL, TC, FC, CE, bile acid profile | Enzymatic assay, colorimetric assay, HPLC, LC-MS/MS | Concentration after dilution correction |
Liver tissue | TBA, TC, FC, CE, HL, CYP7A1, FABP1/LFABP, BLVRB | Microassay, activity assay, ELISA, LC-MS/MS | Normalized to wet weight or protein amount |
Intestinal tissue/intestinal cells | NPC1L1, bile acid-related indicators, cholesterol-related indicators | ELISA, microassay, LC-MS/MS | Normalized to tissue weight, protein amount, or cell number |
Gallbladder-related samples | CCK, CCKAR, biliary lipid indicators | ELISA, colorimetric assay, microassay | Correlation analysis with gallbladder function or bile discharge status |
4 Indicator Combinations in Application Scenarios
4.1 Cholestasis and Abnormal Biliary Excretion
(1) Basic combination
Studies of cholestasis or abnormal biliary excretion should prioritize TBA, TBIL, and DBIL detection, with bile samples or liver tissue indicators added according to the sample source. Increased TBA may indicate bile acid accumulation, while increased DBIL is more suggestive of abnormal conjugated bilirubin excretion. Their combined use is more informative than either indicator alone for assessing hepatobiliary excretory status.
(2) Mechanistic extension
If changes in bile acid synthesis and transport need to be explained, CYP7A1, bile acid profiling, or related transporter detection can be added. TBA elevation alone cannot distinguish increased bile acid synthesis, impaired transport, excretory obstruction, or altered enterohepatic circulation. Component analysis or mechanistic indicators should be selected according to the experimental model.
4.2 Bilirubin Metabolism and Jaundice-Related Studies
(1) Basic combination
Bilirubin metabolism studies can use a combination of TBIL, DBIL, urinary bilirubin, and urobilinogen. TBIL and DBIL are used to evaluate bilirubin burden in blood or bile, while urinary bilirubin and urobilinogen serve as auxiliary indicators related to bile pigment excretion and enterohepatic circulation.
(2) Mechanistic extension
Biliverdin/bilirubin metabolism-related proteins such as BLVRB can be used as mechanistic indicators to analyze bile pigment reduction, redox status, and bilirubin metabolic regulation. These indicators do not replace TBIL or DBIL content measurements and are more suitable for explaining changes in bile pigment metabolic pathways.
4.3 Cholesterol Metabolism and Gallstone-Related Studies
(1) Basic combination
Studies of gallstones and biliary lipid composition should not rely solely on total cholesterol detection, but should simultaneously evaluate TC, FC, CE, and bile acid levels. Cholesterol crystallization risk is associated with the ratio of cholesterol, bile acids, and phospholipids; elevated TC alone cannot fully explain changes in biliary micellar stability.
(2) Mechanistic extension
LCAT, NPC1L1, CYP7A1, and HL can be used as mechanistic indicators related to cholesterol esterification, cholesterol absorption, bile acid synthesis, and lipoprotein hydrolysis. If the research objective involves hepato-intestinal cholesterol flux, blood lipid indicators, tissue cholesterol esters, hepatic lipase activity, and bile acid components should be analyzed together.
4.4 Hepatic Lipid Transport and Hepatocellular Injury-Related Studies
(1) Lipid transport
FABP1/LFABP can be used to evaluate changes related to hepatocellular fatty acid binding and transport. It is suitable for fatty liver, abnormal cholesterol metabolism, drug-induced liver injury, and hepatocellular lipid loading models. This indicator is better used as an auxiliary marker of hepatic lipid metabolism and liver injury, and should be combined with TC, FC, CE, LDL-C, HDL-C, or tissue lipid detection.
(2) Sample processing
When detecting hepatic lipase activity, FABP1/LFABP, or other protein indicators in liver tissue or cell samples, protein extraction efficiency, lysis system, centrifugation-based clarification, and protein normalization should be carefully controlled. If the same experiment includes both metabolite content detection and protein indicator detection, compatible extraction systems should be used separately to avoid forcing one pretreatment method to serve all detection purposes.
4.5 Gallbladder Function and Regulation of Bile Discharge
(1) Basic combination
Gallbladder function studies can combine CCK and CCKAR with bile flow, bile acids, bilirubin, and biliary lipid indicators. Changes in CCK or CCKAR suggest that gallbladder contraction and bile discharge regulation may be altered, but they do not independently represent changes in bile composition.
(2) Sample design
Gallbladder-related studies should distinguish serum hormone levels, receptor expression in gallbladder tissue, and changes in bile composition whenever possible. If CCK, bile acids, and biliary lipids are included in the same experiment, their respective meanings should be clearly defined: regulatory signal, bile acid metabolism, and bile composition. They should not be treated as indicators of the same category.
Table 4 Recommended Indicator Combinations in Hepatobiliary Metabolism Studies
Research Direction | Core Indicators | Extended Indicators | Method Combination |
Cholestasis | TBA, TBIL, DBIL | Bile acid profile, CYP7A1 | Microassay/colorimetric assay + LC-MS/MS/ELISA |
Jaundice and bilirubin metabolism | TBIL, DBIL, urinary bilirubin, urobilinogen | BLVRB | Microassay + qualitative chromogenic assay + ELISA |
Gallstones and biliary lipids | TC, FC, CE, TBA | Bile acid profile, LCAT | COD-PAP method/microassay + LC-MS/MS/ELISA |
Cholesterol absorption and transport | TC, FC, CE, LDL-C, HDL-C | NPC1L1, LCAT, HL | Colorimetric assay + COD-PAP method + ELISA/activity assay |
Hepatic lipid metabolism | TC, FC, CE, HL | FABP1/LFABP | Microassay + activity assay + ELISA |
Gallbladder function | CCK, CCKAR | Bile acids, bilirubin, bile flow | ELISA + content detection |
Enterohepatic circulation | TBA, bile acid profile, urobilinogen | NPC1L1, CYP7A1 | Microassay + LC-MS/MS + ELISA |
5 Result Interpretation and Quality Control
5.1 Standard Curve and Linear Range
(1) Linear range
Content detection of TBA, TBIL, DBIL, TC, FC, CE, and related indicators should ensure that sample readings fall within the linear range of the standard curve. Bile, hyperlipidemic serum, and high-concentration tissue homogenates can easily exceed this range; suitable dilution factors should therefore be determined through pilot experiments.
(2) Dilution linearity
Dilution linearity should be verified for samples with complex matrices. If calculated results differ across dilution factors, this suggests matrix interference, insufficient background subtraction, or reaction inhibition. Dilution ratio, centrifugation/clarification, or sample blank settings should then be optimized.
5.2 Blanks and Matrix Interference
(1) Sample blanks
Sample blanks should be included for bile, tissue homogenates, lipemic samples, and colored samples. Bile itself is deeply colored and contains high levels of bilirubin and lipids. Without background subtraction, colorimetric or fluorescence assay results may be overestimated.
(2) Spike recovery
Spike recovery can be used to evaluate whether the matrix affects the detection signal. Low recovery suggests extraction loss or reaction inhibition, whereas high recovery may be associated with insufficient background subtraction or signal enhancement by interfering substances. This is particularly relevant for bile, feces, tissue homogenates, and culture medium samples.
5.3 Normalization and Intergroup Comparison
(1) Tissue and cell normalization
Tissue samples can be normalized to wet weight, protein amount, or homogenate volume, while cell samples can be normalized to protein amount, cell number, or total DNA amount. Different normalization methods affect result interpretation; therefore, the same standard should be maintained within a single experiment.
(2) Multi-indicator integrated interpretation
Hepatobiliary metabolism studies should not rely on a single indicator. Increased TBA, increased DBIL, altered TC/FC ratio, CE accumulation, altered HL activity, or abnormal CCK levels point to different layers of biological change. Only by integrating content detection, activity assays, mechanistic indicators, and sample source can hepatobiliary metabolic status be assessed more accurately.
Table 5 Common Abnormal Results and Optimization Strategies
Abnormal Finding | Possible Cause | Optimization Strategy |
Excessively high TBA reading | High bile acid concentration, insufficient dilution, reading outside the linear range | Increase dilution factor and verify dilution linearity |
High TBIL/DBIL background | Deep sample color, insufficient blank subtraction | Set sample blanks and optimize clarification |
Large replicate variation in TC or FC | Insufficient mixing of lipid-rich samples, pipetting error | Mix thoroughly and use calibrated pipettes |
Low CE result | Insufficient extraction efficiency or improper sample storage | Optimize extraction procedure and reduce freeze-thaw cycles |
Abnormal variation in HL activity | Improper sample storage, reduced enzyme activity, or inconsistent reaction conditions | Standardize sampling, storage, reaction temperature, and detection time |
Unstable urinary bilirubin result | Improper urine storage, light exposure, or drug interference | Use fresh samples and control storage conditions |
Large batch-to-batch variation in ELISA | Differences in standard curve, incubation conditions, or plate washing | Detect key samples in the same batch and strictly standardize procedures |
Low LC-MS/MS response | Ion suppression, unsuitable internal standard, extraction loss | Optimize sample pretreatment and use internal standard correction |
6 Selection of Related Products and Materials
Table 6 Core Content and Activity Detection Products for Hepatobiliary Metabolism
Cat. No. | Product Name | Grade & Purity | Indicator Category | Application Positioning |
Total Bile Acids (TBA) Content Assay Kit (Micro Method) | BioReagent | Bile acid metabolism | Detection of total bile acid levels in serum, plasma, bile, tissue, or cell samples; suitable for evaluating cholestasis and bile acid metabolism | |
Total Bilirubin (TBIL) Content Assay Kit (Micro Method) | BioReagent | Bilirubin metabolism | Detection of total bilirubin content; suitable for studies of bile pigment metabolism, cholestasis, and hepatobiliary excretory abnormalities | |
Direct Bilirubin (DBIL) Content Assay Kit (Micro Method) | BioReagent | Bilirubin metabolism | Detection of direct/conjugated bilirubin; suitable for evaluating biliary excretion, cholestasis, and bilirubin metabolism | |
Urine Bilirubin Qualitative Detection Kit (Harrison's Method) | BioReagent | Auxiliary urinary bile pigment indicator | Qualitative detection of urinary bilirubin; suitable for auxiliary screening of hepatobiliary excretory abnormalities and bilirubin metabolism-related changes | |
Urobilinogen Qualitative Detection Kit (Modified Ehrlich's Method) | BioReagent | Auxiliary urinary bile pigment indicator | Qualitative detection of urobilinogen; suitable for evaluating bilirubin enterohepatic circulation and urinary auxiliary indicators | |
Total Cholesterol (TC) Content Assay Kit (Single-Reagent COD-PAP, Micro Method) | BioReagent | Cholesterol metabolism | Microassay detection of total cholesterol; suitable for studies of biliary lipid composition, hepatic cholesterol metabolism, and gallstone-related mechanisms | |
Total Cholesterol (TC) Content Assay Kit (Double-Reagent COD-PAP, Micro Method) | BioReagent | Cholesterol metabolism | Dual-reagent microassay for total cholesterol; suitable for batch samples and complex matrix analysis | |
Total Cholesterol (TC) Content Assay Kit (Single-Reagent COD-PAP, Colorimetric Method) | BioReagent | Cholesterol metabolism | Routine colorimetric detection of total cholesterol; suitable for spectrophotometric or conventional colorimetric systems | |
Free Cholesterol (FC) Content Assay Kit (COD-PAP, Micro Method) | BioReagent | Free cholesterol | Microassay detection of free cholesterol; suitable for studies of biliary lipid composition, cholesterol crystallization, and gallstone risk | |
Free Cholesterol (FC) Content Assay Kit (Single Reagent COD-PAP, Colorimetric Method) | BioReagent | Free cholesterol | Single-reagent colorimetric detection of free cholesterol; suitable for routine sample analysis | |
Free Cholesterol (FC) Content Assay Kit (Dual Reagent COD-PAP, Colorimetric Method) | BioReagent | Free cholesterol | Dual-reagent colorimetric detection of free cholesterol; suitable for detection systems requiring reduced background interference | |
Cholesterol Ester (CE) Content Assay Kit for Liquid Samples (Micro Method) | BioReagent | Cholesterol ester | Detection of cholesterol esters in serum, plasma, bile, and other liquid samples; suitable for studies of cholesterol esterification and lipid transport | |
Cholesterol Ester (CE) Content Assay Kit for Tissues/Cells (Micro Method) | BioReagent | Cholesterol ester | Detection of cholesterol esters in liver tissue, gallbladder tissue, or cell models; suitable for evaluating tissue/cellular cholesterol storage | |
Total Cholesterol and Cholesteryl Ester Fluorometric Assay Kit | BioReagent, colorimetric assay, for analytical use | Total cholesterol/cholesterol ester | Combined detection of total cholesterol and cholesterol esters; suitable for cholesterol metabolism and biliary lipid composition analysis | |
Low Density Lipoprotein Cholesterol (LDL-C) Content Assay Kit (COD-PAP, Micro Method) | BioReagent | Lipoprotein cholesterol | Microassay detection of LDL-C; suitable as an auxiliary indicator for hepatic cholesterol transport and blood lipid metabolism | |
Low-Density Lipoprotein Cholesterol (LDL-C) Content Assay Kit (COD-PAP, Colorimetric Method) | BioReagent | Lipoprotein cholesterol | Colorimetric detection of LDL-C; suitable for auxiliary evaluation of blood lipid metabolism and hepatic lipid transport | |
High Density Lipoprotein Cholesterol (HDL-C) Content Assay Kit (COD-PAP, Micro Method) | BioReagent | Lipoprotein cholesterol | Microassay detection of HDL-C; suitable for auxiliary evaluation of reverse cholesterol transport and hepatic lipid metabolism | |
High-Density Lipoprotein Cholesterol (HDL-C) Content Assay Kit (COD-PAP, Colorimetric Method) | BioReagent | Lipoprotein cholesterol | Colorimetric detection of HDL-C; suitable for studies of blood lipid metabolism and cholesterol transport | |
Hepatic Lipase (HL) Activity Assay Kit (Micro Method) | BioReagent | Hepatic lipase activity | Microassay detection of hepatic lipase activity; suitable for studies of hepatic lipid hydrolysis, lipoprotein metabolism, and blood lipid regulation | |
Liver Esterase (HL) Activity Assay Kit (Micro Method) | BioReagent | Hepatic esterase/hepatic lipase activity | Microassay detection of hepatic esterase activity; suitable for evaluating hepatic lipid metabolism and changes in enzyme activity | |
Liver Esterase (HL) Activity Assay Kit (Colorimetric Method) | BioReagent | Hepatic esterase/hepatic lipase activity | Colorimetric detection of hepatic esterase activity; suitable for conventional spectrophotometric detection systems |
Table 7 Products Related to Mechanistic Studies of Hepatobiliary Metabolism
Cat. No. | Product Name | Grade & Purity | Indicator Category | Application Positioning |
Human Lecithin Cholesterol Acyltransferase (LCAT) ELISA Kit | BioReagent | Cholesterol esterification/lipoprotein metabolism | LCAT detection in human samples; suitable for studies of cholesterol esterification, HDL metabolism, and lipoprotein remodeling | |
Rat Lecithin Cholesterol Acyltransferase (LCAT) ELISA Kit | BioReagent | Cholesterol esterification/lipoprotein metabolism | LCAT detection in rat models; suitable for mechanistic studies of hepatic cholesterol metabolism | |
Mouse Lecithin Cholesterol Acyltransferase (LCAT) ELISA Kit | BioReagent | Cholesterol esterification/lipoprotein metabolism | LCAT detection in mouse models; suitable for studies of cholesterol esterification and lipoprotein metabolism | |
Mouse Cholesterol 7 Alpha Hydroxylase (CYP7A1) ELISA Kit | BioReagent | Bile acid synthesis | CYP7A1 detection in mice; suitable for studies of cholesterol conversion to bile acids and bile acid synthesis pathways | |
Mouse NPC1-like Intracellular Cholesterol Transporter 1 (NPC1L1) ELISA Kit | BioReagent | Cholesterol absorption/transport | NPC1L1 detection in mice; suitable for studies of intestinal cholesterol absorption and hepato-intestinal cholesterol transport | |
Human Biliverdin Reductase B (BLVRB) ELISA Kit | BioReagent | Bile pigment metabolism | BLVRB detection in human samples; suitable for studies of biliverdin/bilirubin metabolism and redox-related mechanisms | |
Human Cholecystokinin (CCK) ELISA Kit | BioReagent | Gallbladder function regulation | CCK detection in human samples; suitable for studies of gallbladder contraction, bile discharge, and digestive regulation | |
Rat Cholecystokinin (CCk) ELISA Kit | BioReagent | Gallbladder function regulation | CCK detection in rat models; suitable for studies of gallbladder function and bile discharge regulation | |
Rat Cholecystokinin A Receptor (CCKAR) ELISA Kit | BioReagent | Gallbladder function regulation | CCKAR detection in rats; suitable for mechanistic studies related to the cholecystokinin receptor | |
Mouse Cholecystokinin (CCK) ELISA Kit | BioReagent | Gallbladder function regulation | CCK detection in mouse models; suitable for studies of gallbladder contraction and bile discharge | |
Pig Cholecystokinin (CCK) ELISA Kit | BioReagent | Gallbladder function regulation | CCK detection in porcine samples; suitable for studies of digestive regulation and gallbladder function | |
Human Fatty Acid Binding Protein 1, Liver (FABP1) ELISA Kit | BioReagent | Hepatic lipid transport/auxiliary liver injury indicator | FABP1 detection in human samples; suitable for studies of hepatocellular fatty acid transport and liver injury | |
Human L-FABP ELISA Kit | BioReagent | Hepatic lipid transport/auxiliary liver injury indicator | Detection of human liver-type fatty acid-binding protein; suitable for auxiliary evaluation of hepatic lipid metabolism and hepatocellular injury | |
Mouse L-FABP ELISA Kit | BioReagent | Hepatic lipid transport/auxiliary liver injury indicator | Detection of mouse liver-type fatty acid-binding protein; suitable for mouse hepatic lipid metabolism and liver injury models | |
Mouse Fatty Acid Binding Protein 1 (LFABP) ELISA Kit | BioReagent | Hepatic lipid transport/auxiliary liver injury indicator | LFABP detection in mice; suitable for studies of hepatic fatty acid transport and lipid metabolism | |
Hepatic Protein Isolation Kit | BioReagent, for protein analysis, for mammalian sample extraction | Liver tissue protein sample pretreatment | Liver tissue protein extraction; suitable for ELISA, protein analysis, and pretreatment for mechanistic indicator detection |
Detection of hepatobiliary metabolism-related indicators should be combined according to the research objective. Cholestasis studies may prioritize TBA, TBIL, and DBIL; bilirubin metabolism studies may incorporate urinary bilirubin and urobilinogen; cholesterol homeostasis and gallstone studies should combine TC, FC, CE, and lipoprotein indicators. When mechanistic interpretation is required, regulatory factors such as CYP7A1, NPC1L1, LCAT, HL, FABP1/LFABP, and CCK can be further included.
